Insider trade

Officer sold ~$303K of DXCM shares in the open market

Traded Sep 10, 2026 · Filed Sep 14, 2026

DexcomDXCM

~$303K
Reported value · 3,638 sh @ $83.27: 147K
Holds after · shares reported: +2.0%
stock since the trade · S&P 500 +0.8%, $84.51 → $86.23 on Oct 1

Why it stands out

Dexcom's Chief Financal Officer sold $303K of Dexcom shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Sep 10, 2026
Reporting period: Not applicable
Filed with the SEC: Sep 14, 2026

Officer$100K–$500KPre-arranged plan referenced

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$302,936

Shares × reported transaction price

Timing vs results

42 days after results of Jul 30, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $84.51 on Sep 10, 2026, 54% above its 52-week low and 8% below its high, after a 12% rise over the previous 30 trading days

52-week range $54.84 (Nov 10, 2025) to $92.34 (Aug 21, 2026), 79% of the way up, from 251 adjusted closes. 30 trading days earlier: $75.14 on Jul 29, 2026. Describes the past only, not a forecast

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

Securities lawsuit open at the trade date

A securities lawsuit naming the company as a defendant was filed on Oct 27, 2025 in the U.S. District Court, S.D. New York. A filing is an allegation, not a finding.

3 such cases were open. Prime v. DexCom, Inc., docket 1:25-cv-08912, via CourtListener (court records). Nature of suit 850, company named as first defendant

After it was reported

After	Stock	S&P 500	Difference
7 days	+3.6%	+2.1%	+1.4%

Past results only. Not a forecast.

Source receipt

Record ID: 0001093557-26-000173
Filed / recorded: Sep 14, 2026, 8:02 PM UTC
Added to OQRO: Oct 2, 2026, 12:27 PM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: DEXCOM INC
Issuer CIK: 1093557
Ticker: DXCM
Reporting person: Jereme M Sylvain
Relationship: Officer
Officer title: EVP, Chief Financal Officer
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Sep 10, 2026
Transaction code: S
Shares / units: 3,638
Price per share: $83.27
Acquired / disposed: Disposed (D)
Shares owned after: 146,828
Ownership form: Direct
Amendment: No

Footnotes from the filing

On June 10, 2026, Mr. Sylvain adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sylvain. The shares set forth above were sold pursuant to the 10b5-1 Plan.
Included in this number are 87,094 unvested restricted stock units, 48,774 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 23,937 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 5,699 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 8,684 of which were granted on March 8, 2024 and shall vest through March 8, 2027, and 76 additional shares acquired under the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan.

Around the same time

Officer sold ~$221K of Dexcom

Scheduled in advance5d ago

Officer plans to sell ~$221K of Dexcom

Planned, from pay7d ago

Director sold ~$130K of Dexcom

Scheduled in advance3w ago